These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 29247285

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Drug-Drug Multicomponent Solid Forms: Cocrystal, Coamorphous and Eutectic of Three Poorly Soluble Antihypertensive Drugs Using Mechanochemical Approach.
    Haneef J, Chadha R.
    AAPS PharmSciTech; 2017 Aug; 18(6):2279-2290. PubMed ID: 28101724
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Multicomponent solid forms of felodipine: preparation, characterisation, physicochemical and in-vivo studies.
    Chadha R, Sharma M, Haneef J.
    J Pharm Pharmacol; 2017 Mar; 69(3):254-264. PubMed ID: 28134976
    [Abstract] [Full Text] [Related]

  • 5. Quality by design approach for oral bioavailability enhancement of irbesartan by self-nanoemulsifying tablets.
    Patel J, Dhingani A, Garala K, Raval M, Sheth N.
    Drug Deliv; 2014 Sep; 21(6):412-35. PubMed ID: 24215334
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.
    Anusha A, Narendar D, Krishna Murthy B, Goverdhan P.
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):179-185. PubMed ID: 28386752
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Irbesartan treatment in hypertension.
    Brown MJ.
    Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug.
    Chawla G, Bansal AK.
    Eur J Pharm Sci; 2007 Sep; 32(1):45-57. PubMed ID: 17618092
    [Abstract] [Full Text] [Related]

  • 13. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF, Curran MP, Goa KL, Perry CM.
    Drugs; 2004 Sep; 64(9):999-1028. PubMed ID: 15101793
    [Abstract] [Full Text] [Related]

  • 14. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.
    Gillis JC, Markham A.
    Drugs; 1997 Dec; 54(6):885-902. PubMed ID: 9421695
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
    Bramlage P, Schindler C.
    Expert Opin Pharmacother; 2010 Mar; 11(4):521-35. PubMed ID: 20030566
    [Abstract] [Full Text] [Related]

  • 18. Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension.
    Zhang S, Liu P, Jiang S, Hong X, Xing H, Xu X.
    Methods Find Exp Clin Pharmacol; 2005 Apr; 27(3):173-8. PubMed ID: 15834449
    [Abstract] [Full Text] [Related]

  • 19. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.
    Jiang S, Mao G, Zhang S, Hong X, Tang G, Li Z, Liu X, Zhang Y, Wang B, Xu X, Wang X.
    Clin Pharmacol Ther; 2005 Sep; 78(3):239-48. PubMed ID: 16153395
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.